Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Ueno
Observed name:
Makoto Ueno
Institution:
Kanagawa Cancer Center
Observed institutions:
Kurashiki Central Hospital,
Kanagawa Cancer Center
ORCID:
0000-0003-4480-0029
Observed ORCID:
0000-0003-4480-0029
OpenAlex ID:
A5058464052
1527P GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)
2024
·
S. Kobayashi
, A. Ohba
, et al.
·
Annals of Oncology
·
4
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
2026
·
Stephen L. Chan
, Thomas Yau
, et al.
·
Cancer Research Communications
·
2
PDF
98P Subgroup analysis of a phase II study of nanvuranlat in pre-treated, advanced, refractory biliary tract cancer patients (BTC) support an enriched patient population for a planned phase III study
2025
·
M. Ueno
, M. Ikeda
, et al.
·
Annals of Oncology
·
2
322P Ivosidenib in pretreated Japanese (JPN) patients (pts) with mutant isocitrate dehydrogenase 1 (mIDH1) nonresectable/metastatic cholangiocarcinoma (n/mCCA): Phase II study results
2025
·
T. Satake
, Y. Maruki
, et al.
·
Annals of Oncology
·
2
PDF
Abstract 1094: Circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection and recurrence monitoring in hepatocellular carcinoma (HCC); COSMOS-HCC01
2026
·
Masashi Kudo
, Mitsuhito Sasaki
, et al.
·
Cancer Research
·
1
1522P S-1 monotherapy versus nanoliposomal irinotecan plus 5-fluorouracil/leucovorin regimen for second-line therapy of recurrent or metastatic pancreatic cancer (JON 2109-P)
2024
·
Y. Tozuka
, H. Imaoka
, et al.
·
Annals of Oncology
·
1
134TiP A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy
2022
·
H. Imaoka
, M. Sasaki
, et al.
·
Annals of Oncology
·
1
64P Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)
2022
·
M. Ueno
, C. Morizane
, et al.
·
Annals of Oncology
·
1
274TiP A randomized phase 2 study of nanoliposomal irinotecan (nal-IRI, BAX2398)-containing regimen in Japanese patients with metastatic pancreatic adenocarcinoma (mPAC)
2016
·
T. Ioka
, M. Ueno
, et al.
·
Annals of Oncology
·
1
272O TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC): early safety and efficacy results in participants (pts) from Asia
2025
·
D-Y. Oh
, J.O. Park
, et al.
·
Annals of Oncology
383P Real-world outcomes of long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan for the Japanese cohort of NALLONG study
2025
·
M. Ueno
, H. Imaoka
, et al.
·
Annals of Oncology
376P Comparison of S-1 with concurrent radiotherapy or gemcitabine plus nab-paclitaxel combination therapy in patients with locally advanced pancreatic cancer: An integrated analysis of two phase II trials (JCOG2408A)
2025
·
Y. Sano
, R. Kajikawa
, et al.
·
Annals of Oncology
347P Phase II study of lenvatinib plus hepatic intra-arterial infusion chemotherapy (HAIC) with cisplatin followed by surgical resection in patients with borderline resectable hepatocellular carcinoma (BR-HCC): Feasibility results of LEOPARD-Neo study
2025
·
T. Yoh
, K. Watanabe
, et al.
·
Annals of Oncology
387P Real-world evidence on KRAS mutation status in the Japanese population with pancreatic ductal adenocarcinoma
2025
·
K. Shionoya
, Y. Hiroshima
, et al.
·
Annals of Oncology
1001TiP Raludotatug deruxtecan in participants with gastrointestinal cancers: Phase II REJOICE-GI01 trial
2025
·
M. Ueno
, R.S. Finn
, et al.
·
Annals of Oncology
PDF
338P Interim report of the real-world data analysis of pemigatinib therapy for unresectable or recurrent biliary tract cancer patients in Japan with FGFR2 fusion or FGFR2 rearrangement (JON2303 B)
2025
·
Y. Kimura
, T. Ioka
, et al.
·
Annals of Oncology
PDF
370eP Prognostic significance of CA19-9 before conversion surgery for patients with initially unresectable pancreatic cancer
2025
·
S. Kobayashi
, N. Okano
, et al.
·
Annals of Oncology
PDF
MO50-6 Characterization of patients with advanced biliary tract cancer by KRAS alteration subtypes
2024
·
T. Shibuki
, Y. Nakamura
, et al.
·
Annals of Oncology
PDF
1521P Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study
2024
·
H. Imaoka
, M. Ikeda
, et al.
·
Annals of Oncology
74MO Impact of MTAP loss on prognosis and efficacy of immune check point inhibitors across advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-1
2024
·
K. Seguchi
, T. Fujisawa
, et al.
·
Annals of Oncology
PDF
255P Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-transferase P1 for FOLFIRINOX in unresectable pancreatic cancer
2016
·
S. Tezuka
, M. Ueno
, et al.
·
Annals of Oncology
Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer (YCOG001).
2011
·
M. Ueno
, S. Ohkawa
, et al.
·
Journal of Clinical Oncology
6594 Phase II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
2009
·
C. Morizane
, T. Okusaka
, et al.
·
European Journal of Cancer Supplements
Show more works
View as search
Works count:
23
Citation count:
15
H-index:
2
I10-index:
Year
Topic
Type